TFF Pharmaceuticals publishes research on intranasal delivery of mAbs

TFF Pharmaceuticals announced the publication of research demonstrating the feasibility of intranasal delivery of monoclonal antibodies, or mAbs, using the company’s proprietary Thin Film Freezing technology. The paper, entitled “Feasibility of Intranasal Delivery of Thin-film Freeze-dried Monoclonal Antibodies”, was first published on October 24. More specifically, the research assessed the feasibility of applying the company’s Thin Film Freezing technology to convert mAbs into aerosolizable dry powders that can be delivered into the posterior nasal cavity using Aptar Pharma’s Unidose Powder Nasal Spray System. Based on the results of these studies, researchers concluded that, with proper formulation compositions, subjecting mAbs to Thin Film Freezing did not cause an increase in high molecular weight species and the mass percentage of proteinaceous particles remained below 2% weight concentration (w/w). Maintaining low molecular weight for droplet/particle size distribution is considered to be a critical attribute for effective delivery of intranasal liquid products.